Toronto Region Board of Trade’s Post

🚀 Exciting News from BioVivium Strategies! 🚀 We are thrilled to announce the spinout of BioVivium Biotech, a pioneering step forward in our mission to revolutionize healthcare. With a dedicated focus on innovative secretome therapies, BioVivium Biotech aims to harness the power of cellular communication to develop treatments that address a multitude of diseases. 🔬 What is Secretome Therapy? Secretome therapy involves the use of proteins and other factors secreted by cells, which can promote repair and fight disease. This cutting-edge approach has the potential to transform treatment paradigms across various conditions. 🌐 Our Journey BioVivium Biotech emerges from BioVivium Strategies’ commitment to pushing the boundaries of biomedical research and innovation. As a new entity, BioVivium Biotech will drive the development and commercialization of our proprietary secretome-based therapies, moving closer to clinical application and widespread patient benefit. We are initiating a feasibility study to rigorously test and validate our innovative therapies, ensuring they meet the highest standards of efficacy and safety. 💡 Our Vision We believe in a future where secretome therapies will play a crucial role in regenerative medicine and beyond. Our talented team at BioVivium Biotech is poised to lead this change, creating impactful health solutions that are effective, safe, and accessible. Join us in celebrating this milestone as we continue to pursue breakthroughs that improve lives. Stay tuned for more updates on our progress and discoveries! https://lnkd.in/e628st6A #BioViviumBiotech #SecretomeTherapy #BiotechInnovation #HealthcareRevolution #SpinoutSuccess #FeasibilityStudy

👁️✨ Breakthrough in Vision Restoration: Life Biosciences' Groundbreaking Data! ✨👁️ Exciting news from the forefront of biotech! Life Biosciences has presented revolutionary data at ARVO, demonstrating the restoration of visual function in nonhuman primates. This is a monumental leap forward in the quest to combat vision loss and age-related visual decline! 🌟🧬 The ability to restore sight is no longer a distant dream but a rapidly approaching reality. Life Biosciences' innovative approach not only offers hope for millions suffering from visual impairments but also paves the way for broader applications in regenerative medicine. 🚀🔬 This achievement is a testament to the incredible progress being made in the field of longevity and healthspan extension. As we continue to push the boundaries of what's possible, the future looks brighter—literally and figuratively! 🌍💡 The article for those who want to know more is here: https://lnkd.in/gWJKyaRt What do you think about this groundbreaking development? How will it impact the future of healthcare and longevity? Let's discuss! Comment below! 👇💬 PS. If you're interested in Longevity, come join our Ikare Longevity Community and get free access to longevity experts (doctors, sports coaches, dietitians, etc.): https://ikare.ai/community thanks! #Biotech #VisionRestoration #LifeBiosciences #ARVO #Longevity #HealthTech #IkareCommunity

"My dream is to put Toronto at the centre of a global endeavour to bring these advanced medicines to patients in a way that has never been done before." Michael May will be the keynote at next week's (August 20) regenerative medicine breakfast series hosted by Toronto Region Board of Trade. Scroll down to hear Dr. May's thoughts on progress in the field of regenerative medicine, Toronto's role, how the business community can lend support, and much more. Continuing from above, here is the rest of Dr. May's answer to the question "Given the global interest in this field, what is the business case for keeping research and investment in the Toronto region?" A: "We are launching CCRM hubs around the world, and these hubs will work together to tackle the global market, but with Canada at the centre. Why shouldn't Canada be at the centre of this? Canada, Ontario, and Toronto have the right combination of scientific legacy, collaborative ecosystem, and infrastructure to lead in this field. Our long-term goal is to ensure that Toronto remains the focal point of this transformative industry, leading the way in making regenerative medicine a reality for patients worldwide." With lots of great speakers on the agenda (Mitchel Sivilotti, Emily Titus, Shaf Keshavjee, Alison Nankivell, Maura Campbell), we hope you join us next week. Register here: https://lnkd.in/gmNSSzhT

My BioCentury Inc. read this week spotlights 2023 translational literature on new Alzheimer's mechanisms emerging from academia 🔬. This insightful article utilised BioCentury’s Distillery, a curated database of potential investment opportunities from academia, to shed light on groundbreaking research that could reshape our understanding of the disease. Kudos to the researchers paving the way for innovative approaches to tackle Alzheimer's. Let's stay informed and support advancements in the field! 🧠💡 #AlzheimersResearch #InnovationInScience #HealthcareAdvancements

Smart biomaterials and regenerative medicine have advanced to the peak of innovation and science in Brabant. With a vibrant ecosystem of research institutions, universities, and cutting-edge companies, the region has emerged as a global hub for pioneering breakthroughs in this revolutionary domain.   To further enhance this sector, Mike Houtkamp from Brabantse Ontwikkelings Maatschappij (BOM) represented the Invest in Holland network at the Cell & Gene Meeting on the Med in Rome, a premier event uniting international experts and companies in the field of Regenerative Medicine. Alongside colleagues from the Invest in Holland network, ROM Utrecht Region, the aim was to attract companies active in regenerative medicine to strengthen the Regmed Cluster in the Netherlands.   In #Brabant, the Smart BioMaterials Consortium (SBMC) is part of RegMed XB, a network of 4 initiatives that together form the Dutch national RG pilot plant for regenerative medicine. In Leiden, NecstGen is working on new cell and gene therapies. UMC Utrecht is responsible for the development of micro-tissues and in Maastricht ReGEN Biomedical provides macro-tissues that are needed for the development of personalized regenerative therapies.   SBMC manages a development facility on the TU/e campus and a facility for pilot production. Recently, it was announced that Smart BioMaterials Consortium (SBMC), Brabantse Ontwikkelings Maatschappij (BOM), and High Tech Infosystems NL are joining forces to promote biomedical innovation. This partnership will contribute to further advancement and collaboration within the sector.  #BOM #BRABANTISBRIGHT

𝐀𝐮𝐭𝐨𝐧𝐨𝐦𝐨𝐮𝐬 𝐔𝐧𝐢𝐯𝐞𝐫𝐬𝐢𝐭𝐲 𝐨𝐟 𝐁𝐚𝐫𝐜𝐞𝐥𝐨𝐧𝐚 𝐚𝐧𝐝 𝐎𝐫𝐠𝐚𝐧𝐨𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐣𝐨𝐢𝐧 𝐟𝐨𝐫𝐜𝐞𝐬 𝐭𝐨 𝐝𝐞𝐯𝐞𝐥𝐨𝐩 𝐧𝐞𝐰 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐏𝐚𝐫𝐤𝐢𝐧𝐬𝐨𝐧’𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 🤝 Parkinson’s Disease affects millions of people worldwide, and there is an urgent need of novel therapeutics to stop the disease progression and increase patients’ life quality 💊 The Universitat Autònoma de Barcelona and OrganoTherapeutics now have agreed to jointly work on a program for the development of new therapeutics against Parkinson’s disease . This is based on the work of Professor Salvador Ventura, who leads the Protein Folding and Conformational Disorders’ group at the IBB UAB. His team investigates protein structure, function and aggregation, with a focus on neurodegenerative diseases like Parkinson’s. In the future UAB and OT will jointly further develop candidate molecules which have been initially developed in the Ventura lab. We are eager to start working on this project and continue advancing our research on therapeutics for neurodegeneration 🧠 #Collaboration #Parkisonsdisease #Organoids 

🚀 Exciting Partnership Announcement! 🚀 🔬 Boehringer Ingelheim partners with UK biotech Ochre Bio to tackle chronic liver disease. 💰 Up to $1bn partnership to develop treatments harnessing liver's regenerative capacity. 🔍 Ochre Bio's approach: - Analysing thousands of human livers to understand disease causes. - Studying RNA changes to extend lifespan of transplanted livers. - Aiming to 'nudge' liver cells to regenerate. 💡 Partnership aims to address unmet needs in advanced liver disease. 👨🔬 Boehringer sees Ochre Bio's genomics expertise as key to uncovering regenerative pathways. Exciting times ahead in liver disease treatment! 🌟 #machinelearning #biotech #drugdiscovery

Great summary of some of the content at #LATSS2024 in this blog.

Great insights shared by @DaveBlivin from Cottonwood Technology Fund on how venture groups are stepping up to support early innovation, particularly in the fields of genomics and precision medicine. As larger companies scale back, the role of venture groups in promoting new and innovative ideas becomes more crucial than ever. Dave highlights the importance of investing in these areas early on to drive progress and improve patient outcomes. #innovation #venturecapital #genomics #precisionmedicine

As things settle down after the Translational Science Summit, we're reflecting on all of the amazing sessions that took place throughout the day. We've pulled together some key takeaways about translational science in the UK from some of the main sessions – just a snippet from a jam-packed day! These are: - Collaboration is key - Be bold, ambitious and innovative - Getting regulation right is essential - The UK can become the go-to place for clinical trials - We need to unite to deliver impact for the patients - Fail to prepare, prepare to fail - Being proactive and pro-innovation can unleash UK life sciences Read more in our latest blog: https://shorturl.at/nqxIS